Gunnar Henrik Heine/X
Jun 23, 2025, 13:27
Gunnar Henrik Heine: Apixaban Substantially Safer than Rivaroxan for Initial Treatment of VTE
Gunnar Henrik Heine, Professor of Internal Medicine at Saarland University, Editor of Nephrology Dialysis Transplantation (NDT), shared a post on X:
“RivaGate in DC at ISTH 2025. In COPRRA, apixaban was substantially safer than rivaroxan for initial (3 mo) treatment of VTE.
Lana Castellucci for this arguably most important DOAC study ever.”
More posts from ISTH 2025 on Hemostasis Today.
-
Feb 21, 2026, 15:58Addressing Underdiagnosis and Care Inequities in Women and Girls with Bleeding Disorders – WFH
-
Feb 21, 2026, 15:49Sheharyar Raza: The Leaky Pipeline of AI and Machine Learning in Transfusion Medicine
-
Feb 21, 2026, 15:21Joanna Sadowska: Watching a Stem Cell Divide Reveals Life’s Blueprint
-
Feb 21, 2026, 14:43Gashaw Arega: Demonstrating Impact Through Blood Donation for Childhood Cancer
-
Feb 21, 2026, 14:42Travel Tips for Attending WFH 2026 World Congress in Kuala Lumpur
-
Feb 21, 2026, 13:56Tagreed Alkaltham: Transfusion Misidentification – When Identity Errors Become Fatal
-
Feb 21, 2026, 13:46Timothy Stalker: Differences Between Arterial and Venous Hemostasis
-
Feb 21, 2026, 13:36Augustina Isioma Ikusemoro: Strengthening Awareness and Prevention on World Anaemia Awareness Day
-
Feb 21, 2026, 13:20Mary Cushman: Novel Proteins Shed Light on the Mechanisms of VTE